Brief: Ondine Biomedical Says Topline Results From Lantern Phase 3 Study Expected Within Six Weeks
13/07/2026 07:20
BRIEF-Ondine Biomedical Says Topline Results From Lantern Phase 3 Study Expected Within Six Weeks July 13 (Reuters) - Ondine Biomedical Inc OBI.L:
ONDINE BIOMEDICAL - UPDATE ON US PHASE 3 PIVOTAL STUDY
ONDINE BIOMEDICAL - TOPLINE RESULTS FROM LANTERN PHASE 3 STUDY EXPECTED WITHIN SIX WEEKS
ONDINE BIOMEDICAL - PRIMARY ENDPOINT AND SUCCESS CRITERIA FOR LANTERN PHASE 3 STUDY REMAIN UNCHANGED
Source text: ID:nRSM0552Ma
Further company coverage: OBI.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ondine Biomedical
See all newsAIM Ondine Biomedical - Capital Access Window - Ondine Biomedical Inc
Brief: Ondine Biomedical Confirms Total Gross Proceeds From Placing And Subscription Are £10 Million
Ondine Biomedical - Result of Fundraise, Restoration of Trading & TVR
Brief: Ondine Biomedical Announces A Proposed Fundraising Of About £10 Mln
Ondine Biomedical - Proposed c.£10m (C$18.88m) Fundraise